Kaiser taps ultrasound providers
Ultrasound vendors Acuson and Siemens Ultrasound are the latest recipients of contracts from HMO Kaiser Permanente. After naming Acuson to be its sole provider of radiology and vascular ultrasound systems (SCAN 9/3/97), Kaiser has also named Acuson its
Ultrasound vendors Acuson and Siemens Ultrasound are the latest recipients of contracts from HMO Kaiser Permanente. After naming Acuson to be its sole provider of radiology and vascular ultrasound systems (SCAN 9/3/97), Kaiser has also named Acuson its selected vendor for cardiac ultrasound systems in adult, pediatric, intraoperative, and stress echocardiography applications.
As part of the two-year, sole-source agreement, Kaiser will buy replacement and additional Sequoia C256 and Aspen echocardiography systems over the term of the contract. The agreement also includes two single-year extension options, according to Mountain View, CA-based Acuson. Kaiser's previous preferred vendor for cardiac ultrasound was Hewlett-Packard.
In another Kaiser contract, the HMO awarded Siemens Ultrasound a two-year agreement to be its sole provider of ob/gyn, emergency-room, and urology ultrasound scanners. Under the terms of the deal, Kaiser will purchase multiple Sonoline Prima systems. The contract is valued at $1 million per year, according to the Issaquah, WA-based firm.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
